Lisheng Pharmaceutical released a report for the third quarter of 2021, with operating income of 248 million yuan, down 17.66% from the same period last year. Net profit belonging to shareholders of listed companies was 36.4642 million yuan, up 61.33% from the same period last year. Net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses was 35.7928 million yuan, up 57.46% from the same period last year; and basic earnings per share was 0.20 yuan.

According to the 2021 report of Lisheng Pharmaceutical, the company's main income was 587 million yuan, down 4.32% from the same period last year; the net profit was 61.2528 million yuan, up 8.28% from the same period last year; and deducting 58.6519 million yuan from non-net profit, up 4.93% from the same period last year. Among them, in the second quarter of 2021, the company's main income in a single quarter was 260 million yuan, down 7.63% from the same period last year; and the net profit in a single quarter was 25.1983 million yuan, up 12.92% from the same period last year. The non-net profit in a single quarter was 23.3118 million yuan, down 8.71% from the same period last year; the debt ratio was 14.68%, the investment income was 7.7881 million yuan, the financial expenses were-26.0877 million yuan, and the gross profit margin was 58.27%.

The stock has no agency rating in the last 90 days. In the past three months, the net outflow of financing was 17.8549 million, and the financing balance decreased; the net inflow of securities was 0, and the balance of securities lending increased. According to the Securities Star valuation analysis tool, Lisheng Pharmaceutical (002393) has a 2-star rating, a good price rating of 2 stars, and a comprehensive valuation rating of 2 stars.

The chairman of the company is Xu Daoqing. Mr. Xu Daoqing: born in August 1962, Chinese nationality, no permanent residence abroad, on-the-job graduate degree, bachelor's degree, senior engineer. He has successively served as the project leader, director, deputy director, deputy sales minister, marketing minister and deputy general manager of the Research Institute of Tianjin Central Pharmaceutical Co., Ltd.; the factory director of Tianjin Zhongxin Pharmaceutical Co., Ltd. is also the deputy general manager of Tianjin Zhongxin Pharmaceutical Group Co., Ltd.; party committee secretary, deputy factory director of Tianjin Zhongxin Pharmaceutical Longshunrong Pharmaceutical Factory, general manager of Tianjin Xinfeng Pharmaceutical Co., Ltd. Deputy General Manager and Chief engineer of Tianjin Zhongxin Pharmaceutical Group; Director and Deputy General Manager of Tianjin Lisheng Pharmaceutical Co., Ltd.; Party General Branch Secretary, Director, Vice Chairman and General Manager of Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd. He is currently the party committee secretary, director and chairman of Tianjin Lisheng Pharmaceutical Co., Ltd., and the director and chairman of Tianjin Tianbian Pharmaceutical Co., Ltd.

This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If there are any questions in the article, please contact us.